|
|
 |
|
Viewing report
|
|
|
|
Branded vs Generic Drugs in Russia and CEE – Expert Insights
FirstWord Publishing, July 2010, Pages: 43
Across Russia and former Communist countries in Central and Eastern Europe, the battle for market share is being played out on three fronts between patented drugs, branded and commodity generics.
And it’s not surprising. While consumers prefer the status of innovative patented drugs produced by recognizable Western pharma giants, they are culturally attached to inexpensive, government-subsidized products. And as more and more patented blockbusters go off-patent, branded generics and commodity products alike have gained ground.
Yet the barriers to winning the hearts and wallets of consumers in the region are considerable. Government reimbursement schemes encourage the use of commodity generic brands, which are four times less expensive than patented medications. Legal issues abound, too. Competition between branded and commodity drugs often leads to intellectual property court battles and patent disputes. And in a region well-supported by generics companies, innovative drug brands are often priced out of competition.
Even so, many experts believe that despite the crowded market, there is still room for new entrants in many categories. Branded vs Generic Drugs in Russia and CEE – expert insights assesses the pharma landscape in CEE countries, including Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russia and Slovakia. The report offers an historical perspective cast against economics, cultural preferences and most importantly, the current market climate. Featuring case studies, key insights and interview transcripts with pharmaceutical leaders in the region, the report defines the scope of pharma’s challenges in the region.
The report offers insights into:
- The current climate market, broken down by branded and generic sectors
- How innovative pharmaceutical companies can make inroads into the region
- The report offers an historical, cultural and economic breakdown of the region
- Reviews which companies are gaining headway, and why
- Includes full transcripts of interviews with key pharmaceutical executives
- Offers case studies from leading companies including Pfizer and Gedeon Richter
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Opportunities in Emerging Markets - Central and Eastern Europe, Russia, and Ukraine
Pharma Market Insights: Generics
Generic and Innovative Drugs Market in Russia and Ukraine 2011 - Comparative Analysis, Reimbursement Policies and Development Forecasts for 2011-2013
Russia Pharmaceutical Market Overview Pharma companies target Russia despite the challenges it presents
Will Big Pharma Find Success in Generics?
Pharmaceutical Pricing and Reimbursement in Russia
State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma
IMS Country Review: Russian Federation
State of the Pharmaceutical Industry 2011 - Industry Remodeling Activities
Pharmaceuticals - Global Outlook
|
|
|
|
